DanCann Pharma A/S (NGM:DANCAN)

Market Cap	3.97M
Revenue (ttm)	6.36M
Net Income (ttm)	-16.88M
Shares Out	3.99M
EPS (ttm)	-4.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,123
Average Volume	22,871
Open	0.6600
Previous Close	0.6050
Day's Range	0.6000 - 0.6800
52-Week Range	0.5900 - 18.8000
Beta	1.96
RSI	41.93
Earnings Date	Oct 27, 2025

About DanCann Pharma

DanCann Pharma A/S, a biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing therapeutic cannabinoids in various disease areas. It sources, develops, and distributes prescription and over-the-counter cannabinoid-based pharmaceuticals primarily focused on pain patients. The company’s development pipeline includes EXT02 CannGros, EXT03 CannGros, EXT04 CannGros, FLS04 CannGros, and FLS05 CannGros. It is also involved in the import and distribution of Bedrocan CannGros, Bedica CannGros, and Bediol CannGros...

• Industry: Pharmaceutical Preparations
• Founded: 2018
• Employees: 5
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: DANCAN

Financial Performance

In 2024, DanCann Pharma's revenue was 7.37 million, an increase of 3.06% compared to the previous year's 7.15 million. Losses were -8.35 million, -86.59% less than in 2023.

Financial numbers in DKK